Clinical Trials
28
Trial Phases
5 Phases
Drug Approvals
24
Drug Approvals
Saccharomyces boulardii capsules
- Product Name
- 亿活
- Approval Number
- 国药准字SJ20150052
- Approval Date
- Jul 28, 2020
Saccharomyces boulardii sachets
- Product Name
- 亿活
- Approval Number
- 国药准字SJ20150051
- Approval Date
- Jul 12, 2020
Clinical Trials
Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials
Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ)
- Conditions
- Dravet SyndromeChildhoodPediatric EpilepsyEpilepsyEpileptic Encephalopathy
- Interventions
- Drug: Stiripentol capsule (Diacomit®)Drug: Stiripentol oral suspension (Diacomit®)
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Biocodex
- Target Recruit Count
- 24
- Registration Number
- NCT07176832
- Locations
- 🇫🇷
3 Chemin d'Armancourt, Compiègne, France
🇫🇷EUROFINS OPTIMED, 1 rue des Essarts, Gières, France
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
- Conditions
- IBS (Irritable Bowel Syndrome)IBS-D (Diarrhea-predominant)IBS, Mixed Symptoms
- Interventions
- Drug: Saccharomyces Boulardii 250 MGDrug: Placebo 250 mg
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-11
- Lead Sponsor
- Biocodex
- Target Recruit Count
- 406
- Registration Number
- NCT07168434
The Effect of Mucogyne® Ovule on Wound Healing (ORIGYNE)
- Conditions
- Cervicovaginitis
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-09-05
- Lead Sponsor
- Biocodex
- Target Recruit Count
- 144
- Registration Number
- NCT06585579
- Locations
- 🇫🇷
CHU Amiens-Picardie, Amiens, France
🇫🇷CHU Besançon, Besançon, France
🇫🇷Hôpital Nord Franche-Comté, Trévenans, France
Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3
- Conditions
- Primary Hyperoxaluria Type 1Primary Hyperoxaluria Type 2Primary Hyperoxaluria Type 3
- Interventions
- Drug: Placebo Oral CapsuleBiological: Urine samples collectBiological: Blood samples collectOther: Kidney imagingOther: Quality of Life questionnaires
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Biocodex
- Target Recruit Count
- 42
- Registration Number
- NCT06465472
Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))
- Conditions
- Erythema Migrans of Lyme Disease
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- Biocodex
- Target Recruit Count
- 120
- Registration Number
- NCT06451913
- Locations
- 🇸🇮
University Medical Centre Ljubljana, Ljubljana, Slovenia
- Prev
- 1
- 2
- 3
- 4
- Next
News
MRM Health Secures €55 Million Series B to Advance Microbiome-Based Therapeutics for Inflammatory Diseases
MRM Health NV raised €55 million in Series B funding led by Biocodex to advance its microbiome-based therapeutic pipeline, including Phase 2b trials for lead program MH002 in ulcerative colitis.
Global Clinical Trials for Dravet Syndrome Reviewed in 2024
• A new report offers an overview of the clinical trial landscape for Dravet Syndrome, also known as Severe Myoclonic Epilepsy of Infancy, providing key data and analysis. • The review includes data on trial numbers, average enrollment, and top countries involved, segmented by region, phase, status, endpoints, and sponsor type. • Key companies like Jazz Pharmaceuticals, UCB, Takeda, and others are profiled, with details on their ongoing trials and prominent drugs in development for Dravet Syndrome. • The report identifies trends in clinical trial enrollment over the past five years and highlights recent news related to Dravet Syndrome research and development.